Stem Cell Oversight Committee (SCOC)-approved human embryonic stem cell lines

The following human embryonic stem cell lines were reviewed by the Stem Cell Oversight Committee (SCOC), found to conform to the Tri-Agency Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2) or, prior to December 9, 2014, the Guidelines for Human Pluripotent Stem Cell Research, and approved by CIHR’s Governing Council.

Research proposals conducted under the auspices of an institution eligible to administer Agency funds and that use these cell lines need to be reviewed and approved by SCOC, and their institutional Research Ethics Board before the work can commence.

SCOC-approved human embryonic stem cell lines
Cell Line Source
CA1, CA2 Lunenfeld-Tanenbaum Research Institute
Mount Sinai Hospital
CC1, CC3 University of Calgary
CyT49 CyThera, Inc.
Elf1 (limited to non-commercial uses) WiCell
ES2, ES3, ES4, ES5, ES6 Centre for Regenerative Medicine of Barcelona
ESI-017, ESI-035, ESI-049, ESI-051, ESI-053 ESI BIO
H1, H7, H9, H14 WiCell
HAD-C 102, HAD-C 104, HAD-C 106 Hadassah Human Embryonic Stem Cell Research Center
hES1, hES2, hES3, hES4, hES5, hES6 ESI BIO
HSF-6 University of California, San Francisco
HUES 1-28, 64 HSCI iPS Core, Harvard University
I3, I6 Technion-Israel Institute of Technology
KCL-003-CF1 King's College
MEL1, MEL2 Millipore Corporation
RUES1-3 The Rockefeller University
VUB01, VUB02, VUB03_DM1, VUB04_CF, VUB05_HD, VUB06, VUB08_MFS, VUB09_FSHD, VUB10_SCA, VUB11_FXS, VUB12_FXS, VUB13_DM1, VUB14, VUB19_DM1, VUB20_CMT1A, VUB22_CF, VUB23_OI, VUB24_DM1, and VUB28_HD_MFS (each limited to non-commercial uses) Vrije Universiteit Brussel
WIBR1, WIBR2, WIBR3 Whitehead Institute
UCLA 1-18, UCLA 19n, UCLA 20n University of California, Los Angeles
Date modified: